000 01177 a2200337 4500
005 20250514212759.0
264 0 _c20050413
008 200504s 0 0 eng d
022 _a0007-0963
024 7 _a10.1111/j.1365-2133.2004.06277.x
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aSimeone, P
245 0 0 _aEndothelin-1 could be one of the targets of psoriasis therapy.
_h[electronic resource]
260 _bThe British journal of dermatology
_cDec 2004
300 _a1273-5 p.
_bdigital
500 _aPublication Type: Letter; Research Support, Non-U.S. Gov't
650 0 4 _aAtrasentan
650 0 4 _aCells, Cultured
650 0 4 _aDermatologic Agents
_xpharmacology
650 0 4 _aEndothelin-1
_xantagonists & inhibitors
650 0 4 _aHumans
650 0 4 _aKeratinocytes
_xdrug effects
650 0 4 _aPsoriasis
_xdrug therapy
650 0 4 _aPyrrolidines
_xpharmacology
700 1 _aTeson, M
700 1 _aLatini, A
700 1 _aCarducci, M
700 1 _aVenuti, A
773 0 _tThe British journal of dermatology
_gvol. 151
_gno. 6
_gp. 1273-5
856 4 0 _uhttps://doi.org/10.1111/j.1365-2133.2004.06277.x
_zAvailable from publisher's website
999 _c15288565
_d15288565